These findings propose Hsp90 and CDK4 as novel targets of ritonavir in NSCLC and suggest that ritonavir’s inhibition of CDK4 may increase the sensitivity of NSCLC cells to DNA replication-associated stress [54]. The gene discussed is CDK4; the disease is non-small cell lung carcinoma.